Modern approach to travellers diarrhea treatment
Abstract
The aim of review. To define etiological factors, features of clinical pattern and up-to-date approaches to treatment of travellers diarrhea.
Original positions of the review. Travellers diarrhea most often develops at visits to tropical countries. In the majority of cases low sanitary-and-hygienic level in host country contributes to its development, and etiological agent is enterotoxigenic strains E. coli. The basic role in treatment is given to rehydration therapy, and prescription of antibiotics. Thus nonabsorbable antibiotics (rifaximin) have a lot of advantages in comparison to systemically acting antibiotics.
Conclusion. Keeping of prophylactic measures allows to decrease the risk of development of travellers diarrhea, and rehydration therapy with prescription of nonabsorbable antibiotics helps to stop clinical signs of disease faster.
References
1. Castelli F., Saleri N., Tomasoni L.R., Carosi G. Prevention and treatment of traveler’s diarrhea. Focus on antimicrobial agents // Bacterial flora in digestive disease. Focus on Rifaximin / Eds. C. Scarpignato, A. Lanas. – Basel: Karger, 2006. – P. 174–190.
2. DuPont H.L., Ericsson C.D., Mathewson J.J. et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea // Digestion. – 1998. – Vol. 59. – P. 708–714.
3. DuPont H.L., Zhi-Dong Jiang, Okhuysen P.C. et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea // Ann. Intern. Med. – 2005. – Vol. 142. – P. 805–812.
4. Farthing M.J.G. Antisecretory drugs for diarrheal disease // Recent advances in gastrointestinal pharmacology and therapeutics / Eds. C. Scarpignato, F. Di Mario. – Basel: Karger, 2006. – P. 74–94.
5. Gascon J. Epidemiology, etiology anf pathophysiology of traveler’s diarrhea // Bacterial flora in digestive disease. Focus on Rifaximin / Eds. C. Scarpignato, A. Lanas. – Basel: Karger, 2006. – P. 162–173.
6. Jiang Z.D., DuPont H.L. Rifaximin: in vitro and in vivo antibacterial activity – a review // Chemotherapy. – 2005. – Vol. 51. (suppl. 1). – P. 67–72.
7. Johnson S., Schriever Ch., Galang M. Interruption of recurrent Clostridium difficile associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Brief report // Clin. Infect. Dis. – 2007. – Vol. 44. – P. 1–3.
8. Scarpignato C., Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic // Bacterial flora in digestive disease. Focus on Rifaximin / Eds. C. Scarpignato, A. Lanas. – Basel: Karger, 2006. – P. 15–39.
9. Steffen R., Sack D.A., Riopel L. et al. Therapy of travelers’ diarrhea with rifaximin on various continents // Am. J. Gastroenterol. – 2003. – Vol. 98. – P. 1073–1078.
10. Taylor D.N., Bourgeois A.L., Ericsson C.D. et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers’ diarrhea // Am. J. Trop. Med. Hyg. – 2006. – Vol. 74. – P. 1060–1066.
11. Wingate D., Phillips S.E., Lewis S.J. et al. – Guidelines for adults on self-medication for the treatment of acute diarrhea // Aliment. Pharmacol. Ther. – 2001. – Vol. 15. – P. 773–782.
Review
For citations:
Sheptulin A.A. Modern approach to travellers diarrhea treatment. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2008;18(6):64-67. (In Russ.)
Views:
115
JATS XML
Email this article 
